Figure 5
Selection of optimal chemotherapeutic drug combinations using the nanodroplet cell processing platform. (a) Fluorescent detection of live PC-3 cells by Calcein AM labeling (green color) under the treatments with cisplatin (5 and 10 μg/ml), paclitaxel (0.6 and 1.2 μg/ml), doxorubicin (10 and 20 μg/ml), 5-FU (500 and 1000 μg/ml), and their combinations after 24 h. Details can be referred in Supplementary Table 1. Scale bar, 1 mm. (b) Regression coefficients evaluated from the stepwise linear regression model. (c) Cell viabilities of PC-3 cells under the combinational treatments of cisplatin (Cis), paclitaxel (Pac) and doxorubicin (Dox) with different concentrations. The selected drug optimization is highlighted by the red arrow. Each data represents the mean ± SD from 3 independent experiments (*p < 0.05 and **p < 0.01). (d) Comparison of cell viabilities obtained from the single-drug treatment and the optimal combination (mean ± SD from 2~3 independent experiments; ***p < 0.001).
